Holen Sie sich die Stockscreener-App
79.49
1.28%
-1.03
Handel nachbörslich:
79.49
Schlusskurs vom Vortag:
$80.52
Offen:
$81
24-Stunden-Volumen:
351.43K
Relative Volume:
1.01
Marktkapitalisierung:
$1.81B
Einnahmen:
$923.71M
Nettoeinkommen (Verlust:
$84.68M
KGV:
20.17
EPS:
3.9419
Netto-Cashflow:
$182.81M
1W Leistung:
-2.65%
1M Leistung:
+0.19%
6M Leistung:
-4.03%
1J Leistung:
+22.94%
1-Tages-Spanne:
$78.38
$81.00
1-Wochen-Bereich:
$78.38
$83.66
52-Wochen-Spanne:
$62.60
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(609) 759-1810
Adresse
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
79.49 | 1.81B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $114.17, Implies 44% Upside - TradingView
ANI Pharmaceuticals Inc (ANIP) Valuation: PE, PB & Fair Value Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANI Pharmaceuticals Inc (ANIP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANI Pharmaceuticals Inc (ANIP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANI Pharmaceuticals Inc (ANIP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANI Pharmaceuticals Inc (ANIP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Institutional Confidence - TradingKey
ANI Pharmaceuticals Inc (ANIP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock - Investing.com UK
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals (ANIP) VP sells 500 shares under 10b5-1 plan - Stock Titan
ANI Pharmaceuticals (ANIP) Stock Valuation After Recent Momentum And Cortrophin Growth Prospects - Sahm
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu - GuruFocus
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock - Investing.com
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock By Investing.com - Investing.com India
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027 - Stock Titan
ANI Pharmaceuticals (ANIP) director receives 4,357-share restricted stock award - Stock Titan
ANI Pharmaceuticals (ANIP) director sells 2,000 shares under plan - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - Yahoo Finance
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push - Yahoo Finance
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth - Yahoo Finance
CenterBook Partners LP Purchases Shares of 19,226 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock - Investing.com UK
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock By Investing.com - Investing.com South Africa
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
[144] ANI PHARMACEUTICALS INC SEC Filing - Stock Titan
ANI Pharmaceuticals, Inc. $ANIP Stock Holdings Trimmed by Global Alpha Capital Management Ltd. - MarketBeat
ANIP (NASDAQ: ANIP) broker files Form 144 for 11,862-share sale - Stock Titan
How ANI’s Estradiol Gel Recall at ANI Pharmaceuticals (ANIP) Has Changed Its Quality-Control Investment Story - Yahoo Finance
What ANI Pharmaceuticals (ANIP)'s Recall, Raised Guidance and Buybacks Could Mean For Shareholders - Sahm
ANI Pharmaceuticals Revenue Grows 20 Percent in Q1 2026 Financial Results - asatunews.co.id
ANIP Stock Price, Quote & Chart | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
ANI Pharmaceuticals Inc (ANIP) Stock Down 3.2% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term - Yahoo Finance
ANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program - MSN
ANI Pharmaceuticals (ANIP) Edges Higher: Approaching Key Resistance LevelsWeak Sell Signals - The Legal Advocate
ANI Pharmaceuticals (ANIP) expected to beat earnings estimates: Should you buy? - MSN
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Penn Capital Management Company LLC Increases Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals Holds Steady Near Support as Trading Volume EasesBreakout Confirmation - The Legal Advocate
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Lisanti Capital Growth LLC - MarketBeat
Precision Trading with Ani Pharmaceuticals Inc. (ANIP) Risk Zones - Stock Traders Daily
ANI Pharmaceuticals (ANIP) Q1 earnings: What to expect - MSN
ANI Pharmaceuticals (ANIP) Q1 2026 Earnings: Revenue Beat, Guidance, and Stock DropNews and Statistics - IndexBox
ANI Pharmaceuticals (NASDAQ: ANIP) investors back directors, pay and stock plan - Stock Titan
Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks - Yahoo Finance
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.23%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):